Explanipedia

Supplementary Data from Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery Open

Nicolás A. Giraldo, Sneha Berry, Étienne Becht, Deniz Ateş Özdemir, Kara M. Schenk , et al. · 2023

Supplementary Table S1. Clinicopathologic characteristics of the cohort separated by death at the 5-year time point. Supplementary Table S2. Primary and secondary antibody information and TSA dye pairings for multiplex IF panel. Supplement…

Data from Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery Open

Nicolás A. Giraldo, Sneha Berry, Étienne Becht, Deniz Ateş Özdemir, Kara M. Schenk , et al. · 2023

Multiplex immunofluorescence (mIF) can detail spatial relationships and complex cell phenotypes in the tumor microenvironment (TME). However, the analysis and visualization of mIF data can be complex and time-consuming. Here, we used tumor…

Supplementary Data from Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery Open

Nicolás A. Giraldo, Sneha Berry, Étienne Becht, Deniz Ateş Özdemir, Kara M. Schenk , et al. · 2023

Supplementary Table S1. Clinicopathologic characteristics of the cohort separated by death at the 5-year time point. Supplementary Table S2. Primary and secondary antibody information and TSA dye pairings for multiplex IF panel. Supplement…

Data from Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery Open

Nicolás A. Giraldo, Sneha Berry, Étienne Becht, Deniz Ateş Özdemir, Kara M. Schenk , et al. · 2023

Multiplex immunofluorescence (mIF) can detail spatial relationships and complex cell phenotypes in the tumor microenvironment (TME). However, the analysis and visualization of mIF data can be complex and time-consuming. Here, we used tumor…

Supplementary Data from PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison Open

Joel Sunshine, Peter Nguyen, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry , et al. · 2023

Supplemental Figures S1 Figure S2, Figure S3 and Table S1 and Table S2

Supplementary Data from PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison Open

Joel Sunshine, Peter Nguyen, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry , et al. · 2023

Supplemental Figures S1 Figure S2, Figure S3 and Table S1 and Table S2

Data from PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison Open

Joel Sunshine, Peter Nguyen, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry , et al. · 2023

Purpose: PD-L1 expression in the pretreatment tumor microenvironment enriches for response to anti-PD-1/PD-L1 therapies. The purpose of this study was to quantitatively compare the performance of five monoclonal anti-PD-L1 antibodie…

Data from PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison Open

Joel Sunshine, Peter Nguyen, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry , et al. · 2023

Purpose: PD-L1 expression in the pretreatment tumor microenvironment enriches for response to anti-PD-1/PD-L1 therapies. The purpose of this study was to quantitatively compare the performance of five monoclonal anti-PD-L1 antibodie…

Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery Open

Nicolás A. Giraldo, Sneha Berry, Étienne Becht, Deniz Ateş Özdemir, Kara M. Schenk , et al. · 2021

Multiplex immunofluorescence (mIF) can detail spatial relationships and complex cell phenotypes in the tumor microenvironment (TME). However, the analysis and visualization of mIF data can be complex and time-consuming. Here, we used tumor…

Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade Open

Sneha Berry, Nicolás A. Giraldo, Benjamin Green, Tricia R. Cottrell, Julie E. Stein , et al. · 2021

Astronomy accelerates tumor imaging Immunohistochemical stains for individual markers revolutionized diagnostic pathology decades ago but cannot capture enough information to accurately predict response to immunotherapy. Newer multiplex im…

AstroPath Pipeline Open

Benjamin Green, J. Roskes, Margaret Eminizer, Richard Wilton, Sigfredo Soto-Diaz , et al. · 2021

No description provided.

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial Open

Cathy Eng, Tae Won Kim, Johanna C. Bendell, Guillem Argilés, Niall C. Tebbutt , et al. · 2019

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) Open

Sneha Berry, Nicolás A. Giraldo, Peter K. Nguyen, Benjamin Green, Haiying Xu , et al. · 2019

After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab Open

Nicolás A. Giraldo, Peter Nguyen, Elizabeth L. Engle, Genevieve J. Kaunitz, Tricia R. Cottrell , et al. · 2018

While the binomial presence or absence of PD-L1 expression in the TME was not sufficient to predict response to anti-PD-1 in patients with MCC, we show that quantitative assessments of PD-1+ and PD-L1+ cell densities as well as the geograp…

Melanoma subtypes demonstrate distinct PD-L1 expression profiles Open

Genevieve J. Kaunitz, Tricia R. Cottrell, Mohammed Lilo, Valliammai Muthappan, Jessica Esandrio , et al. · 2017

Biodegradable brain-penetrating DNA nanocomplexes and their use to treat malignant brain tumors Open

Panagiotis Mastorakos, Clark Zhang, Eric Song, Youngeun Kim, Hee Won Park , et al. · 2017

PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison Open

Joel Sunshine, Peter Nguyen, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry , et al. · 2017

Purpose: PD-L1 expression in the pretreatment tumor microenvironment enriches for response to anti-PD-1/PD-L1 therapies. The purpose of this study was to quantitatively compare the performance of five monoclonal anti-PD-L1 antibodies used …

Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats Open

Clark Zhang, Elizabeth Nance, Panagiotis Mastorakos, Jane Chisholm, Sneha Berry , et al. · 2017

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma Open

Paul Nghiem, Shailender Bhatia, Evan J. Lipson, Ragini R. Kudchadkar, Natalie Miller , et al. · 2016

BackgroundMerkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses are transie…

Enhancing intracranial delivery of clinically relevant non-viral gene vectors Open

Sneha Berry, Panagiotis Mastorakos, Clark Zhang, Eric Song, Himat Patel , et al. · 2016

Densely PEGylated poly-l-lysine gene vectors (DNA-BPN) provide more widely distributed transgene expression in the brain, compared to conventionally PEGylated counterparts (DNA-CPN).

Biodegradable DNA Nanoparticles that Provide Widespread Gene Delivery in the Brain Open

Panagiotis Mastorakos, Eric Song, Clark Zhang, Sneha Berry, Hee Won Park , et al. · 2015

Successful gene therapy of neurological disorders is predicated on achieving widespread and uniform transgene expression throughout the affected disease area in the brain. However, conventional gene vectors preferentially travel through lo…

Measurement of PD-L1 in melanoma: a quantitative antibody comparison Open

Joel Sunshine, Sneha Berry, Jessica Esandrio, Haiying Xu, Aleksandra Ogurtsova , et al. · 2015

Meeting abstracts Immunohistochemical detection of PD-L1 may be used in the future as a biomarker to help select an immunotherapeutic regimen for patients with advanced melanoma. For example, patients whose tumors are PD-L1+ may receive an…

Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma Open

Sneha Berry, Janis M. Taube · 2015

Oncogenic driver mutations in several tumor types promote constitutive PD-L1 expression, a crucial ligand in PD-1-mediated tumor immune escape. Our studies in melanoma suggest a different mechanism-one of "adaptive immune resistance" in wh…

Highly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the Brain Open

Panagiotis Mastorakos, Clark Zhang, Sneha Berry, Yumin Oh, Seulki Lee , et al. · 2015

Gene delivery to the central nervous system (CNS) has potential as a means for treating numerous debilitating neurological diseases. Nonviral gene vector platforms are tailorable and can overcome key limitations intrinsic to virus‐mediated…

Sneha Berry YOU? Author Swipe